BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©The Author(s) 2026.
World J Hepatol. Feb 27, 2026; 18(2): 114346
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114346
Table 4 Comparison of baseline and endpoint clinical data between tenofovir amibufenamide and entecavir groups in patients with chronic hepatitis B, n (%)/median (interquartile range)/mean ± SD
VariablesETV (n = 96)
TMF (n = 48)
Baseline
Endpoint
P value
Baseline
Endpoint
P value
DNA positive96 (100.00)25 (26.04)< 0.00148 (100.00)15 (31.25)< 0.001
HBsAg (log10IU/mL)3.50 (3.07-4.00)3.36 (2.97-3.67)0.0873.66 (3.07-4.37)3.37 (3.02-3.89)0.175
HBeAg positive46 (47.92)38 (39.58)0.24421 (43.75)20 (41.67)0.837
TBIL (μmol/L)15.8 (12.1-22.9)13.1 (10.1-17.3)0.00615.8 (11.9-23.7)12.4 (9.5-16.3)0.010
Alb (g/L)45.6 (43.0-47.5)45.44 ± 2.870.67444.8 (42.4-45.9)45.35 ± 2.510.050
ALT (U/L)53.2 (29.0-87.8)23.3 (16.8-32.5)< 0.0145.8 (29.2-74.8)26.3 (17.7-42.5)< 0.01
AST (U/L)37.7 (28.2-65.8)23.8 (19.3-30.6)< 0.0135.9 (24.1-57.1)22.7 (19.1-32.3)< 0.01
GGT (U/L)27.0 (17.0-53.7)21.0 (14.2-28.8)0.01331.2 (18.2-59.5)23.3 (15.0-35.8)0.027
ALP (U/L)79.7 (65.7-95.7)75.04 ± 20.900.10786.4 (68.6-101.2)82.28 ± 24.970.575
TG (mmol/L)1.07 (0.80-1.62)1.14 (0.87-1.45)0.4811.24 (0.86-1.75)1.38 (0.90-1.91)0.354
TC (mmol/L)4.43 (3.88-4.86)4.39 (3.86-4.91)0.9774.53 (4.05-4.76)4.62 (4.32-4.91)0.096
FBG (mmol/L)5.00 (4.68-5.35)4.98 (4.63-5.46)0.9795.00 (4.76-5.29)5.10 (4.77-5.32)0.866
SCr (μmol/L)66.48 ± 14.1471.17 ± 13.870.02167.01 ± 11.1267.76 ± 11.360.745
eGFR (mL/minute/1.73 m2) 111.83 ± 10.16106.10 ± 12.27< 0.001112.50 ± 10.28111.01 ± 10.530.485
BUN (mmol/L)4.18 ± 1.004.41 ± 1.140.1494.33 ± 1.114.64 ± 1.060.160
HGB (g/L)148 (135-159)147 (135-158)0.947147 (135-159)148 (137-158)0.840
PLT (× 109/L)201 ± 60198 ± 610.694196 ± 55198 ± 520.793
LSM (kPa)7.2 (6.0-10.3)6.8 (5.4-8.5)0.1507.0 (6.0-7.6)6.8 (5.5-7.8)0.322
Liver cirrhosis10 (10.42)12 (12.50)0.6505 (10.42)4 (8.33)0.726


Write to the Help Desk